Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER

Atherosclerosis

Volumn 200, Issue 1, 2008, Pages 109-114

  Polisecki, Eliana ^a   Muallem, Hind ^b   Maeda, Nobuyo ^b   Peter, Inga ^c   Robertson, Michele ^d   McMahon, Alex D ^d   Ford, Ian ^d   Packard, Christopher ^d   Shepherd, James ^d   Jukema, J Wouter ^e   Westendorp, Rudi G J ^e   de Craen, Anton J M ^e   Buckley, Brendan M ^f   Ordovas, Jose M ^g   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f University College Cork and INFANT Centre   (Ireland)

^g TUFTS UNIVERSITY   (United States)

Author keywords

Coronary heart disease (CHD); Genetics; HMGCR gene; LDLR gene; Low density lipoproteins (LDLs); Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; RECEPTORS, LDL; RISK FACTORS; TRIGLYCERIDES;

EID: 49949088790     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.12.004     Document Type: Article

References (19)

1. Goldstein J.L., and Brown M.S. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
2. Hobbs H.H., Russell D.W., Brown M.S., and Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24 (1990) 133-170
3. Goldstein J., Hobbs H., and Brown M. Familial hypercholesterolemia. 7th ed. (1995), McGraw-Hill, New York p. 1981-2030
4. Goldstein J.L., and Brown M.S. The low-density lipoprotein pathway and its relation to atherosclerosis (1977), Annual Review Inc, CA p. 897-903
5. Muallem H., North K.E., Kakoki M., et al. Quantitative effects of common genetic variations in the 3′UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study. Hum Genet 121 (2007) 421-431
6. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton Jr. V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 29 (2004) 2821-2827
7. Shepherd J., Blauw G.J., Murphy M.B., et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. Prospective study of pravastatin in the elderly at risk. Am J Cardiol 84 (1999) 1192-1197
8. Shepherd J., et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
9. Havekes L.M., de Knijff P., Beisiegel U., Havinga J., Smit M., and Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 28 (1987) 455-463
10. Lahoz C., Osgood D., Wilson P.W., Schaefer E.J., and Ordovas J.M. Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem 42 (1996) 1817-1823
11. Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113 (1995) 157-166
12. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158 (2001) 183-194
13. Wilson P.W.F., Schaefer E.J., Larson M.G., and Ordovas J.M. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscl Thromb Vasc Biol 16 (1996) 1250-1255
14. Lahoz C., Schaefer E.J., Cupples L.A., et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154 3 (2001) 529-537
15. Lewontin P.C. The interaction of selection and linkage. II. Optimum models. Genetics 50 (1964) 757-782
16. Singer J.B., et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 48 (2007) 2072-2078
17. Expert Treatment Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
18. Baigent C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
19. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. J Am Med Assoc 298 (2007) 776-785